ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
92,248.89
-2.95%
S&P 500
5,918.25
0.00%
Dow Jones
42,635.20
0.00%
US Dollar vs Yen
157.7715
-0.29%
Brent Oil
76.425
0.57%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. ProQR Therapeutics NV (PRQR)

  7. ProQR Therapeutics NV (PRQR) ニュース

PRQR

ProQR Therapeutics NV (PRQR)

ProQR Therapeutics NV
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:PRQR
日付受信時刻ニュースソース見出しコード企業名
2024/12/1222 : 22Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:PRQRProQR Therapeutics NV
2024/12/1206 : 01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRQRProQR Therapeutics NV
2024/12/1121 : 07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRQRProQR Therapeutics NV
2024/12/1022 : 05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRQRProQR Therapeutics NV
2024/12/0522 : 04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRQRProQR Therapeutics NV
2024/11/0721 : 02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRQRProQR Therapeutics NV
2024/10/2605 : 07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRQRProQR Therapeutics NV
2024/10/2419 : 12Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRQRProQR Therapeutics NV
2024/10/2319 : 18Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRQRProQR Therapeutics NV
2024/10/1113 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRQRProQR Therapeutics NV
2024/10/1105 : 18Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRQRProQR Therapeutics NV
2024/10/0106 : 05Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:PRQRProQR Therapeutics NV
2024/08/0820 : 01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRQRProQR Therapeutics NV
2024/05/2305 : 19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRQRProQR Therapeutics NV
2024/05/0920 : 02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRQRProQR Therapeutics NV
2024/05/0821 : 07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRQRProQR Therapeutics NV
2024/02/1521 : 46Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRQRProQR Therapeutics NV
2024/02/1420 : 08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PRQRProQR Therapeutics NV
2024/02/0920 : 37Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PRQRProQR Therapeutics NV
2024/01/1921 : 08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRQRProQR Therapeutics NV
2024/01/0521 : 08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRQRProQR Therapeutics NV
2023/11/0800 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRQRProQR Therapeutics NV
2023/09/2720 : 06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRQRProQR Therapeutics NV
2023/09/1506 : 20Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PRQRProQR Therapeutics NV
2023/08/0320 : 15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRQRProQR Therapeutics NV
2023/08/0120 : 15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRQRProQR Therapeutics NV
2023/05/1620 : 16Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PRQRProQR Therapeutics NV
2023/04/2519 : 06Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:PRQRProQR Therapeutics NV
2023/04/2505 : 31Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PRQRProQR Therapeutics NV
2023/03/3005 : 55Edgar (US Regulatory)Withdrawal of Registration Statement (rw)NASDAQ:PRQRProQR Therapeutics NV
 Showing the most relevant articles for your search:NASDAQ:PRQR

最近閲覧した銘柄

CCOM
US30
US 30
NASDAQ
MSFT
Microsoft
CCOM
US500
US 500
CCOM
US100
US Tech 100
NASDAQ
AAPL
Apple
FX
USDJPY
US Dollar vs Yen
NYSE
NKE
Nike
NYSE
KO
Coca Cola
SPI
SP500
S&P 500
USOTC
BASFY
BASF (QX)
NYSE
XOM
Exxon Mobil
COIN
DOGEUSD
Dogecoin
USI
USTECH100
US Tech 100
NYSE
MCD
McDonalds
NYSE
CVX
Chevron
AMEX
XLV
Health Care Select Sector
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有